SIRT1 inactivation switches reactive astrocytes to an antiinflammatory phenotype in CNS autoimmunity
W Zhang, D **ao, X Li, Y Zhang… - The Journal of …, 2022 - Am Soc Clin Investig
Astrocytes are highly heterogeneous in their phenotype and function, which contributes to
CNS disease, repair, and aging; however, the molecular mechanism of their functional …
CNS disease, repair, and aging; however, the molecular mechanism of their functional …
Gene and cell therapy for muscular dystrophies: are we getting there?
F Galli, L Bragg, L Meggiolaro, M Rossi… - Human gene …, 2018 - liebertpub.com
In the last few years, significant advances have occurred in the preclinical and clinical work
toward gene and cell therapy for muscular dystrophy. At the time of this writing, several trials …
toward gene and cell therapy for muscular dystrophy. At the time of this writing, several trials …
[HTML][HTML] Alpha-Synuclein and Microglia in Parkinson's Disease: From Pathogenesis to Therapeutic Prospects
H Eo, S Kim, UJ Jung, SR Kim - Journal of Clinical Medicine, 2024 - pmc.ncbi.nlm.nih.gov
Parkinson's disease (PD) is a neurodegenerative disorder characterized by both motor
symptoms and non-motor features. A hallmark of PD is the misfolding and accumulation of …
symptoms and non-motor features. A hallmark of PD is the misfolding and accumulation of …
Gene therapy of yeast NDI1 on mitochondrial complex I dysfunction in rotenone-induced Parkinson's disease models in vitro and vivo
H Li, B Sun, Y Huang, J Zhang, X Xu, Y Shen… - Molecular …, 2022 - Springer
Purpose Parkinson's disease (PD) is the second most common neurodegenerative disease
without cure or effective treatment. This study explores whether the yeast internal NADH …
without cure or effective treatment. This study explores whether the yeast internal NADH …
AADC polynucleotides for the treatment of parkinson's disease
US10335466B2 - AADC polynucleotides for the treatment of parkinson's disease - Google
Patents US10335466B2 - AADC polynucleotides for the treatment of parkinson's disease …
Patents US10335466B2 - AADC polynucleotides for the treatment of parkinson's disease …
AADC polynucleotides for the treatment of Parkinson's disease
US11027000B2 - AADC polynucleotides for the treatment of Parkinson's disease - Google
Patents US11027000B2 - AADC polynucleotides for the treatment of Parkinson's disease …
Patents US11027000B2 - AADC polynucleotides for the treatment of Parkinson's disease …
AADC polynucleotides for the treatment of Parkinson's disease
M Scheel, B Ravina - US Patent 11,759,506, 2023 - Google Patents
US11759506B2 - AADC polynucleotides for the treatment of Parkinson's disease - Google
Patents US11759506B2 - AADC polynucleotides for the treatment of Parkinson's disease …
Patents US11759506B2 - AADC polynucleotides for the treatment of Parkinson's disease …
Trajectory array guide system
AP Kells, S Schreck, EH Luttich, KA Bloch… - US Patent …, 2022 - Google Patents
The present disclosure presents a trajectory array guide system for defining a trajectory to a
target location in the brain of a subject and for guiding an elongated tool along the trajectory …
target location in the brain of a subject and for guiding an elongated tool along the trajectory …
Establishment of a Parkinson's disease model and evaluation of therapeutic effects of dopaminergic precursor cellls in a MPTP-treated common marmoset
안재범 - 2020 - s-space.snu.ac.kr
Parkinson's disease (PD) is one of the most important neurodegenerative diseases. Studies
investigating cell transplantation as an alternative to L-3, 4-dihydroxyphenylalanine …
investigating cell transplantation as an alternative to L-3, 4-dihydroxyphenylalanine …
Molecular therapeutic strategies in neurodegenerative diseases and injury
Molecular therapeutics for use in neurodegenerative disease and traumatic injury to the
central nervous system have been implemented widely in preclinical studies and clinical …
central nervous system have been implemented widely in preclinical studies and clinical …